Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca ( (GB:AZN) ) has provided an update.
AstraZeneca reported positive Phase III results for tozorakimab, a potential first-in-class monoclonal antibody targeting interleukin-33 for chronic obstructive pulmonary disease. The drug is designed to inhibit both reduced and oxidised forms of IL-33, aiming to reduce inflammation and break the cycle of mucus dysfunction that drives disease worsening.
In the OBERON and TITANIA trials, tozorakimab met its primary endpoint by significantly lowering annualised moderate-to-severe COPD exacerbation rates versus placebo in former smokers and in the overall patient population on inhaled standard of care. Tozorakimab was generally well tolerated, and the data position AstraZeneca at the forefront of COPD biologics, addressing a major unmet need in a disease that remains the third leading cause of death globally.
Full data from these replicate studies will be presented at an upcoming medical meeting, while additional Phase III trials, PROSPERO and MIRANDA, continue to evaluate long-term outcomes and dosing regimens in COPD. The programme, which also extends to severe viral lower respiratory tract disease and asthma, underscores AstraZeneca’s strategy to expand its respiratory portfolio and strengthen its competitive position in immune-mediated airway disorders.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines. Its core areas include respiratory and immunology, oncology and cardiovascular, renal and metabolism, with a strong emphasis on biologics and targeted therapies for chronic and life-threatening diseases.
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.